Why Do Some Pancreatic Cancers Show Normal Tumor Marker Levels?

It is not uncommon for patients with pancreatic ductal adenocarcinoma—the most common and aggressive form of pancreatic cancer—to present with normal levels of conventional tumor markers, particularly carbohydrate antigen 19-9 (CA 19-9). This phenomenon reflects important biological and clinical realities rather than a laboratory error or diagnostic oversight.

CA 19-9 is synthesized by epithelial cells lining the biliary and pancreatic ducts and is elevated in approximately 70–80% of patients with resectable pancreatic cancer. However, its sensitivity drops significantly in early-stage disease—often remaining within normal limits in stage I tumors—and may be entirely absent in certain molecular subtypes, such as those with low mucin production or neuroendocrine differentiation. Moreover, CA 19-9 expression is genetically determined: individuals who are Lewis antigen-negative (approximately 5–10% of the general population) cannot synthesize CA 19-9 regardless of tumor burden, leading to persistently normal values even in advanced disease.

Other routinely measured markers—including carcinoembryonic antigen (CEA) and CA 125—also lack sufficient sensitivity and specificity for pancreatic cancer screening or diagnosis. CEA is elevated in only about 30–40% of cases, while CA 125 rises primarily in the context of peritoneal involvement or metastatic spread, not early primary disease.

Clinically, reliance on tumor markers alone risks delayed diagnosis. Imaging—particularly contrast-enhanced multiphase CT or MRI with MR cholangiopancreatography (MRCP)—remains the cornerstone of detection. Endoscopic ultrasound (EUS) with fine-needle aspiration provides both high-resolution visualization and histopathologic confirmation when imaging findings are equivocal.

In summary, normal tumor marker levels do not exclude pancreatic cancer. A high index of clinical suspicion—especially in patients with new-onset diabetes, unexplained weight loss, jaundice, or abdominal pain—must guide further investigation, independent of serum biomarker results.